Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli
As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3 (AF3)—the generative AI model developed by Google DeepMind and its commercial sibling, Isomorphic Labs—has fundamentally transformed the landscape of molecular biology. By expanding beyond simple [...]
VenHub Global, Inc. (NASDAQ:VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced the appointment of Ian Rasmussen as
Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.
Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a game-changer for the launch of its experimental weight-loss pill orforglipron, potentially expanding access to millions of patients even as competition with Novo Nordisk intensifies ahead of both companies' earnings.
Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease treatments and gene therapies targeting hearing loss.
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire Ventyx Biosciences (NASDAQ:VTYX) for approximately $1.2 billion. The all-cash deal, valued at $14.00 per share, marks
